CClinicalTrials.gg
CompletedNCT03269266Updated Jan 13, 2020

Scrub Typhus RDT Study

An observational study in The Prevalence of Scrub Typhus, sponsored by Myanmar Oxford Clinical Research Unit. Completed at 2 sites in Myanmar. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by Myanmar Oxford Clinical Research Unit · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
136
Ages
1 Year and older
Sex
All
01

Study summary

Fever is one of most common presenting complaints in clinics in tropical countries. Rickettsial infections, enteric fever and leptospirosis are common and important causes of undifferentiated fever in Southeast Asia. Scrub typhus is caused by Orientia tsutsugamushi and humans are typically infected by a bite of an infected chigger (trombiculid mite larva). Clinical diagnosis is unreliable for identifying scrub typhus, unless a tick eschar is present which is almost pathognomonic for the disease in Southeast Asia. A combination of culture, paired serology and PCR has been proposed as the gold-standard method for detection. As a result laboratory confirmation is not widely available and the diagnosis is missed frequently in clinical practice. Some progress has been made in developing such a test and one promising candidate is the Scrub Typhus Detect IgM Rapid Test (InBios International Inc). We plan to use to this test in this study to estimate the prevalence of scrub typhus in selected febrile patients presenting to clinics in Myanmar .

Patients will be followed up for one week to check for resolution of symptoms.

Read the detailed description

Title: A multicenter observational study to describe the prevalence of scrub typhus defined as s positive rapid diagnostic test among selected patients presenting with fever to clinics in Myanmar.

Rational and objectives of the study Fever is one of most common presenting complaints in clinics in tropical countries. Rickettsial infections, enteric fever and leptospirosis are common and important causes of undifferentiated fever in Southeast Asia. The largest and earliest reports of scrub typhus in Myanmar were made during World War II when this disease afflicted numerous troops, particularly those serving close to the border with India. Scrub typhus is caused by Orientia tsutsugamushi and humans are typically infected by a bite of an infected chigger (trombiculid mite larva). Clinical diagnosis is unreliable for identifying scrub typhus, unless a tick eschar is present which is almost pathognomonic for the disease in Southeast Asia. A combination of culture, paired serology and PCR has been proposed as the gold-standard method for detection. As a result laboratory confirmation is not widely available and the diagnosis is missed frequently in clinical practice. Some progress has been made in developing such a test and one promising candidate is the Scrub Typhus Detect IgM Rapid Test (InBios International Inc). In laboratory-based evaluations using stored sera collected from patients recruited in a study in Thailand with confirmed scrub typhus this test had a sensitivity of \~80% for the detection of the disease compared to serological methods. We plan to use to this test in this study to estimate the prevalence of scrub typhus in selected febrile patients presenting to clinics in Myanmar.

Primary objective: To describe the prevalence of scrub typhus defined as a positive rapid diagnostic test among selected patients presenting with fever to clinics in Myanmar

Secondary objective:

  • To assess inter-observer agreement when interpreting the tests
  • To assess the ease-of-use of the tests
  • To direct future research efforts into rickettsial disease in Myanmar
  • To raise awareness of the presence of scrub typhus in Myanmar Inclusion criteria

    1. Male or female >1 year of age
    2. Fever defined as > 38 °C tympanic temperature
    3. Duration of fever >48h
    4. Written informed consent (by legally acceptable representative in case of children), and assent for children age 10-17 year
    5. Eschar (60 patients only) Exclusion criteria
  • Malaria confirmed by RTD or microscopy
  • Skin/soft tissue infection, dysentery or urinary tract infection probable cause of fever

Procedures and Methodology The study will be carried out to describe the prevalence of scrub typhus defined as a positive rapid diagnostic test among patients presenting with fever to six participating clinics in Myanmar.

Patients coming with fever to participating clinics will be routinely assessment by attending physician. Patients meeting the inclusion and exclusion criteria for the study will be invited and enrolled to the study after getting informed consent.

Rapid diagnostic test and laboratory procedure A scrub typhus rapid test will be performed on site by using the InBios Scrub Typhus Detect IgM Rapid Test. Tests will be read by two independent readers and results recorded as positive, negative or invalid. In case of invalid test result, another test will be performed using a new test strip. If there is any disagreement between two readers, the lead investigator at the site will decide the test result and the test will be photographed.

In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi.

Treatment Physicians will be advised to formulate a treatment plan according to their usual practice but it will be recommended that treatment for scrub typhus be added to the regimen if the test is positive i.e. doxycycline 100mg bd for seven days in adults or 4mg/kg day in two divided doses in children older than eight years. Doxycycline is contraindicated in pregnant women and children eight years old or below and these groups should be prescribed azithromycin (500mg single dose).

Follow up Patients will be reassessed at one week to check for resolution of fever and symptoms . Any patient with ongoing symptoms will be re-assessed by a physician.

Duration and Study Sites Patients will be recruited 1 year starting from December 2017 to November 2018 in six sites: Yae township hospital, No.2, 1000 Bedded Military Hospital (Nay Pyi Taw), No.20, 100 Bedded Military Hospital (Tha Beik Kyin), NAP-MAM clinics (Kawkareik and Putao township), No.2, 300 Bedded Military Hospital (Ann, Rakhine State).

Risk and benefits This is a low risk study. Finger prick for RDT and scrapping from eschar (for patients who have eschar) may cause slight discomfort. Some patients may receive antibiotics they would not have otherwise been prescribed as a result of having the test. However this is most likely to benefit them as these tests have been shown to be sensitive and specific for the diagnosis of scrub typhus in similar settings.

Incentives and Compensation There will be no incentives or compensation for study participation. Confidentiality The study will ensure that the participants' anonymity is maintained. The participants will be identified only by initials and a study number on the CRF and the study database.

Publication The research findings will be disseminated to policy-makers and other interested parties inside Myanmar. If there are any publications resulting from the results all those who have made a substantial contribution will be co-authors.

02

Conditions studied

  • The Prevalence of Scrub Typhus

Keywords

  • Scrub Typhus
  • Positive Rapid Diagnostic Test
03

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with fever (± eschar) presenting to community health clinics/hospitals in Myanmar

Inclusion criteria

  1. Male or female >1 year of age
  2. Fever defined as > 38 °C tympanic temperature
  3. Duration of fever (self-reported) >48h
  4. Written informed consent (by parent or legally acceptable representative in case of children), and assent for children aged 10-17 years
  5. Eschar (60 patients only)

Exclusion criteria

Exclusion Criteria:

  1. Malaria confirmed by RDT or microscopy
  2. Skin/soft tissue infection, dysentery or urinary tract infection probable cause of fever
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
136 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testScrub Typhus RDT Test

    A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid. In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi.

05

What researchers measure

Primary outcomes

  1. Positive RDT Result

    Proportion of patients with a positive RDT result

    Time frame: 15 Minutes

Secondary outcomes

  1. Inter-observer agreement expressed as the kappa statistic

    Ease- of- use of the test (scored on blood safety, quality of instructions, number of timed steps to perform test, ease of interpretation, user satisfaction)

    Time frame: 15 Minutes

  2. Fever/symptom resolution

    Proportion of patients with fever/symptom resolution at one week

    Time frame: One Week

06

Study locations

2 sites
  • No.20, 100 Bedded Military Hospital,
    Thabeikkyin, Mandalay, Myanmar
  • No.2, 1000 Bedded Military Hospital
    Nay Pyi Taw, Myanmar
07

Registry details

Key details

Study ID
NCT03269266
Lead sponsor
Myanmar Oxford Clinical Research Unit
Collaborators
University of Oxford, Medical Action Myanmar, Yae Township Hospital, Mon State, Swiss Tropical & Public Health Institute, Defence Services Medical Academy (DSMA), Myanmar
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Dec 4, 2017
Primary completion
Dec 26, 2019
Completion
Dec 26, 2019
Last update
Jan 13, 2020

Study contacts

Elizabeth Anne Ashley, Dr
study director · Myanmar Oxford Clinical Research Unit
Ni Ni Tun, Dr
study director · Medical Action Myanmar
Aye Thida Aye, Dr
study director · Yae Township Hospital, Mon State
Kyaw Myo Tun, Dr
study director · Defence Services Medical Academy (DSMA)
Khine Khine Su, Prof
study director · Defence Services Medical Academy (DSMA)
James Heaton, Dr
study director · Myanmar Oxford Clinical Research Unit
Kyaw Soe
study director · Myanmar Oxford Clinical Research Unit
Daniel Paris, Prof
study director · Swiss Tropical & Public Health Institute
Frank Smithuis, Prof
principal investigator · Myanmar Oxford Clinical Research Unit and Medical Action Myanmar
Myo Mg Mg Swe, Dr
study director · Myanmar Oxford Clinical Research Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion